Welcome to our dedicated page for Greenwich LifeSciences SEC filings (Ticker: GLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Greenwich LifeSciences, Inc. filings document the reporting, governance, and public-company controls of a clinical-stage biopharmaceutical issuer developing GLSI-100 through the FLAMINGO-01 breast cancer recurrence program. Recent disclosures include a Form 12b-25 notice for a delayed annual report, proxy materials for the annual meeting, and Form 8-K reports on stockholder voting results.
The filing record also covers auditor appointment and change matters, board-election proposals, ratification of the independent registered public accounting firm, and internal-control disclosures referenced in accounting-firm transition materials.
Greenwich LifeSciences, Inc. reported unaudited results for the quarter and six months ended June 30, 2026. The company remains a clinical-stage biopharmaceutical business focused on its Phase III Flamingo-01 trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, and continues to generate no revenue.
For the six months ended June 30, 2026, the company recorded a net loss of $9.6 million, compared with $6.5 million in the prior-year period, driven mainly by higher research and development and stock-based compensation expenses. Research and development spending rose to $8.8 million, while general and administrative expenses reached $1.0 million. Cash used in operations was $6.6 million.
Liquidity is supported primarily by equity raises. During the first half of 2026, Greenwich LifeSciences issued 379,762 shares via At The Market offerings for net proceeds of $9.3 million, increasing cash to $8.9 million as of June 30, 2026 and stockholders’ equity to $3.1 million. The company’s accumulated deficit was $96.7 million.
Management states that recurring losses and negative operating cash flows raise substantial doubt about the ability to continue as a going concern within one year, and notes dependence on additional capital. Management also identifies material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient systems and written procedures, and is developing a remediation plan. Director and insider share lock-ups have been extended through January 31, 2027, after which leak-out provisions will apply.
Snehal Patel, CEO, CFO and more than 10% owner of Greenwich LifeSciences, bought a total of 2,200 shares of common stock in open-market purchases on July 28–29, 2026, at prices of $13.10 and $13.59 per share. The purchases are reported as directly owned and not under a Rule 10b5-1 trading plan.
Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel purchased 1,500 shares of common stock on July 27, 2026 at $13.62 per share in a transaction described as a purchase in open market or private transaction, increasing his direct ownership to 5,609,202 shares. The transaction was not reported as pursuant to a Rule 10b5-1 trading plan.
Greenwich LifeSciences CEO, CFO and 10% owner Snehal Patel purchased a total of 3,600 shares of Common Stock in two reported transactions, buying 2,500 shares at $13.14 per share on July 23, 2026 and 1,100 shares at $12.88 per share on July 24, 2026, all recorded as direct ownership.
Greenwich LifeSciences, Inc. reported a net loss of $5.7 million for the quarter ended March 31, 2026, compared with $2.7 million a year earlier, as it continues developing its breast cancer immunotherapy GLSI-100 and expanding the Phase III Flamingo-01 trial.
Research and development spending rose to $5.2 million from $2.3 million, reflecting higher clinical trial costs, while general and administrative expenses were roughly flat at $0.5 million. The company had $10.5 million of cash on March 31, 2026, funded largely by equity sales through its at-the-market program.
Management states there is substantial doubt about the company’s ability to continue as a going concern within one year without additional capital. The filing also discloses material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient accounting systems.
Greenwich LifeSciences files its annual report describing progress on GP2/GLSI-100, an immunotherapy aimed at preventing HER2/neu‑positive breast cancer recurrence. The company is running the Phase III Flamingo‑01 trial after earlier Phase I/II studies showed encouraging safety and immune responses.
Greenwich remains a clinical‑stage company with no approved products or product revenue. It reported a net loss of $19.4 million for 2025 and $17.4 million for 2024, with an accumulated deficit of $87.1 million, and states it will need significant additional capital to complete development and potential commercialization.
The company highlights substantial risks typical for early‑stage biopharma, including dependence on a single product candidate, reliance on third‑party manufacturers and licensors, intense competition in HER2‑targeted therapies, regulatory complexity in the U.S. and abroad, and uncertainty around future coverage and reimbursement even if GP2 is approved.
Greenwich LifeSciences, Inc. notifies the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and expects to file the report by April 15, 2025, within the fifteen‑calendar‑day extension permitted under Rule 12b-25. The company attributes the delay to effort and expense required to complete the Annual Report.
The filing states research and development expense increased by approximately $4.6 million (about 35%) to $17.5 million for the year ended December 31, 2025 from $12.9 million in 2024, driven primarily by clinical expenses for the Phase III clinical trial; these amounts remain under review and may differ in the final Form 10-K.
Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel, who is also a 10% owner, reported buying additional company stock. On January 13, 2026, he purchased 1,800 shares of common stock at a price of $29.83 per share. Following this open-market purchase, he beneficially owns 5,604,102 common shares, held in direct ownership.
Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock. On 01/12/2026, he purchased 2,900 shares of common stock in an open market transaction coded as a "P" transaction at a price of $27.54 per share.
Following this purchase, Patel directly beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock. The filing reflects direct ownership, with no indirect ownership reported in this transaction.
Greenwich LifeSciences, Inc. reported the results of its Annual Meeting of Stockholders held on December 18, 2025. A total of 8,944,615 shares of common stock were represented in person or by proxy, satisfying quorum requirements.
Stockholders elected all five director nominees — David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock — to serve until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Each nominee received over 7.1 million votes “for,” with no votes “against,” and varying abstentions, alongside broker non-votes.
Stockholders also ratified the appointment of MaloneBailey LLP as the company’s independent registered public accounting firm for the fiscal year ended December 31, 2025, with 8,908,299 votes “for,” 31,459 “against,” and 4,857 “abstain.”